0000000001019662

AUTHOR

Mussini C

showing 2 related works from this author

A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen

2011

Abstract Background HIV-1 genotypic susceptibility scores (GSSs) were proven to be significant prognostic factors of fixed time-point virologic outcomes after combination antiretroviral therapy (cART) switch/initiation. However, their relative-hazard for the time to virologic failure has not been thoroughly investigated, and an expert system that is able to predict how long a new cART regimen will remain effective has never been designed. Methods We analyzed patients of the Italian ARCA cohort starting a new cART from 1999 onwards either after virologic failure or as treatment-naïve. The time to virologic failure was the endpoint, from the 90th day after treatment start, defined as the firs…

OncologyMaleAdult; Anti-HIV Agents; Cohort Studies; Drug Therapy Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Proportional Hazards Models; Treatment Failure; Viral LoadHIV InfectionsCohort Studies0302 clinical medicineANTIRETROVIRAL THERAPYMedicineHIV Infection030212 general & internal medicineTreatment Failure0303 health sciencesHealth PolicyMiddle AgedViral Load3. Good healthComputer Science ApplicationsCensoring (clinical trials)CohortCombinationlcsh:R858-859.7Drug Therapy CombinationFemaleViral loadHumanResearch ArticleCartAdultmedicine.medical_specialtyAnti-HIV AgentsHIV-1; antiretroviral therapyHealth InformaticsSettore MED/17 - MALATTIE INFETTIVElcsh:Computer applications to medicine. Medical informatics03 medical and health sciencesDrug TherapyInternal medicineHumansSurvival analysisProportional Hazards Models030306 microbiologybusiness.industryProportional hazards modelAdult; Anti-HIV Agents; Cohort Studies; Drug Therapy Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Proportional Hazards Models; Treatment Failure; Viral Load; Health Informatics; Health PolicyANTIRETROVIRAL DRUGSAnti-HIV AgentHIVGENOTYPESDiscontinuationRegimenImmunologyProportional Hazards ModelHIV-1Cohort StudiebusinessBMC Medical Informatics and Decision Making
researchProduct

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are creat…

2009

Contains fulltext : 80963.pdf (Publisher’s version ) (Open Access) BACKGROUND: The extent to which mortality differs following individual acquired immunodeficiency syndrome (AIDS)-defining events (ADEs) has not been assessed among patients initiating combination antiretroviral therapy. METHODS: We analyzed data from 31,620 patients with no prior ADEs who started combination antiretroviral therapy. Cox proportional hazards models were used to estimate mortality hazard ratios for each ADE that occurred in >50 patients, after stratification by cohort and adjustment for sex, HIV transmission group, number of antiretroviral drugs initiated, regimen, age, date of starting combination antiretrovir…

MaleInfectious diseases and international health [NCEBP 13]Lymphoma030312 virologyEsophageal candidiasisCohort Studies0302 clinical medicineInterquartile range030212 general & internal medicineAIDS-RelatedLymphoma AIDS-Related0303 health sciencesMortality rateProgressive multifocal leukoencephalopathyHazard ratioPrognosis3. Good healthPathogenesis and modulation of inflammation [N4i 1]Infectious DiseasesCombinationDrug Therapy CombinationFemaleInfection and autoimmunity [NCMLS 1]HumanMicrobiology (medical)Adultmedicine.medical_specialtyPrognosiAnti-HIV Agentsantiretroviral therapyInfectious DiseaseArticleAIDS-Related Opportunistic Infection03 medical and health sciencesAcquired immunodeficiency syndrome (AIDS)Drug TherapyInternal medicinemedicineHumansAIDS-defining eventProportional Hazards ModelsAIDS-Related Opportunistic Infections/diagnosis/ mortality; Acquired Immunodeficiency Syndrome/complications/diagnosis/drug; therapy/ mortality; Adult; Anti-HIV Agents/ therapeutic use; Cohort Studies; Drug Therapy; Combination; Female; Humans; Lymphoma; AIDS-Related/diagnosis/mortality; Male; Prognosis; Proportional Hazards ModelsAcquired Immunodeficiency SyndromeAIDS-Related Opportunistic Infectionsbusiness.industryProportional hazards modelPoverty-related infectious diseases [N4i 3]Anti-HIV Agentmedicine.diseasemortalityConfidence intervalImmunologyProportional Hazards ModelCohort Studiebusiness
researchProduct